Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00740051 · ClinicalTrials.gov registry record · Phase 3
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 227
- Enrollment target
NCT00740051 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 227 participants.
The verdict
NCT00740051, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 227 participants
- Enrollment target
Study Summary
Efficacy of BI 1356 compared to placebo in patients for whom metformin therapy is inappropriate (intolerability, contraindication). The second part of the study looks at the safety of BI 1356 in this patient population with longer term treatment in comparison to a sulfonylurea drug (glimepiride)
Interventions
- DRUG Linagliptin
- DRUG Glimepiride
- DRUG Linagliptin Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00740051
The ClinicalTrials.gov registry entry for NCT00740051 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Linagliptin is the first listed.
NCT00740051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00740051 about?
NCT00740051 is a clinical study titled "A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate". Efficacy of BI 1356 compared to placebo in patients for whom metformin therapy is inappropriate (intolerability, contraindication). The second part of the study looks at the safety of BI 1356 in this patient population with longer term treatment in comparison to a sulfonylurea drug (glimepiride)
What is the current status of trial NCT00740051?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 227 participants. The study started on 2008-08.
What interventions are being tested in trial NCT00740051?
The interventions under investigation include: Linagliptin (DRUG), Glimepiride (DRUG), Linagliptin Placebo (DRUG).
Who is sponsoring clinical trial NCT00740051?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.